Colorado will receive a share of a $95.5 million pharmaceutical settlement 

Colorado will receive more than $376,000 as part of a $95.5 million global settlement with Aventis Pharmaceuticals. The agreement resolves allegations that between 1995 and 2000, Aventis and its corporate predecessors knowingly misreported best prices for the steroid-based anti-inflammatory nasal sprays Azmacort, Nasacort and Nasacort AQ. Under the agreement, state Medicaid programs throughout the country received ...

Comments are closed.